guest ::
| Home > Publications Database > Global and focal white matter integrity in breast cancer survivors 20 years after adjuvant chemotherapy. > print |
| Home > Publications Database > Global and focal white matter integrity in breast cancer survivors 20 years after adjuvant chemotherapy. > print |
| 001 | 137358 | ||
| 005 | 20240321220232.0 | ||
| 024 | 7 | _ | |a 10.1002/hbm.22221 |2 doi |
| 024 | 7 | _ | |a pmid:23281152 |2 pmid |
| 024 | 7 | _ | |a 1065-9471 |2 ISSN |
| 024 | 7 | _ | |a 1097-0193 |2 ISSN |
| 024 | 7 | _ | |a altmetric:1149784 |2 altmetric |
| 037 | _ | _ | |a DZNE-2020-03680 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Koppelmans, Vincent |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a Global and focal white matter integrity in breast cancer survivors 20 years after adjuvant chemotherapy. |
| 260 | _ | _ | |a New York, NY |c 2014 |b Wiley-Liss |
| 264 | _ | 1 | |3 online |2 Crossref |b Wiley |c 2012-12-20 |
| 264 | _ | 1 | |3 print |2 Crossref |b Wiley |c 2014-03-01 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1586864657_18506 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a To date, only four small studies have investigated the effects of adjuvant chemotherapy for breast cancer on the microstructure of cerebral white matter with magnetic resonance imaging (MRI). These studies, which were conducted shortly up to 10 years post-treatment, showed that chemotherapy is associated with focal loss of microstructural white matter integrity. We investigated the long-term effect of chemotherapy on white matter microstructural integrity by comparing the brains of chemotherapy-exposed breast cancer survivors to those of a population-based sample of women without a history of cancer.Diffusion tensor imaging (DTI) MRI (1.5 T) was performed in 187 CMF (cyclophosphamide, methotrexate, and 5-flourouracil) chemotherapy-exposed breast cancer survivors, mean age 64.2 (sd = 6.5) years, who had been diagnosed with cancer on average 21.2 (sd = 4.4) years before, and 374 age-matched cancer-free reference subjects from a population-based cohort study. Outcome measures were whole-brain microstructural integrity as measured by fractional anisotropy and mean/axial/radial diffusivity and focal white matter integrity, which was analyzed with tract-based spatial statistics. All analyses were adjusted for age, cardiovascular risk factors, education, and symptoms of depression.No significant group differences were observed in white matter integrity. However, within the breast cancer survivors, time since treatment was inversely associated with lower global and focal white matter integrity.This cross-sectional study suggests that among chemotherapy-exposed breast cancer survivors white matter microstructural integrity deteriorates with accumulating time since treatment. This warrants further investigation. |
| 536 | _ | _ | |a 345 - Population Studies and Genetics (POF3-345) |0 G:(DE-HGF)POF3-345 |c POF3-345 |f POF III |x 0 |
| 542 | _ | _ | |i 2012-12-20 |2 Crossref |u http://doi.wiley.com/10.1002/tdm_license_1.1 |
| 542 | _ | _ | |i 2012-12-20 |2 Crossref |u http://onlinelibrary.wiley.com/termsAndConditions#vor |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a Antineoplastic Agents |2 NLM Chemicals |
| 650 | _ | 7 | |a Cyclophosphamide |0 8N3DW7272P |2 NLM Chemicals |
| 650 | _ | 7 | |a Fluorouracil |0 U3P01618RT |2 NLM Chemicals |
| 650 | _ | 7 | |a Methotrexate |0 YL5FZ2Y5U1 |2 NLM Chemicals |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a Antineoplastic Agents: adverse effects |2 MeSH |
| 650 | _ | 2 | |a Antineoplastic Combined Chemotherapy Protocols: adverse effects |2 MeSH |
| 650 | _ | 2 | |a Brain: drug effects |2 MeSH |
| 650 | _ | 2 | |a Brain: pathology |2 MeSH |
| 650 | _ | 2 | |a Breast Neoplasms: drug therapy |2 MeSH |
| 650 | _ | 2 | |a Chemotherapy, Adjuvant: adverse effects |2 MeSH |
| 650 | _ | 2 | |a Cross-Sectional Studies |2 MeSH |
| 650 | _ | 2 | |a Cyclophosphamide: administration & dosage |2 MeSH |
| 650 | _ | 2 | |a Cyclophosphamide: adverse effects |2 MeSH |
| 650 | _ | 2 | |a Diffusion Tensor Imaging: instrumentation |2 MeSH |
| 650 | _ | 2 | |a Diffusion Tensor Imaging: methods |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Fluorouracil: administration & dosage |2 MeSH |
| 650 | _ | 2 | |a Fluorouracil: adverse effects |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Leukoencephalopathies: chemically induced |2 MeSH |
| 650 | _ | 2 | |a Leukoencephalopathies: pathology |2 MeSH |
| 650 | _ | 2 | |a Methotrexate: administration & dosage |2 MeSH |
| 650 | _ | 2 | |a Methotrexate: adverse effects |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Survivors |2 MeSH |
| 650 | _ | 2 | |a Time Factors |2 MeSH |
| 700 | 1 | _ | |a de Groot, Marius |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a de Ruiter, Michiel B |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Boogerd, Willem |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Seynaeve, Caroline |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Vernooij, Meike W |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Niessen, Wiro J |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Schagen, Sanne B |0 P:(DE-HGF)0 |b 7 |e Corresponding author |
| 700 | 1 | _ | |a Breteler, Monique M B |0 P:(DE-2719)2810403 |b 8 |e Last author |
| 773 | 1 | 8 | |a 10.1002/hbm.22221 |b : Wiley, 2012-12-20 |n 3 |p 889-899 |3 journal-article |2 Crossref |t Human Brain Mapping |v 35 |y 2012 |x 1065-9471 |
| 773 | _ | _ | |a 10.1002/hbm.22221 |g Vol. 35, no. 3, p. 889 - 899 |0 PERI:(DE-600)1492703-2 |n 3 |q 35:3<889 - 899 |p 889-899 |t Human brain mapping |v 35 |y 2012 |x 1065-9471 |
| 909 | C | O | |p VDB |o oai:pub.dzne.de:137358 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 8 |6 P:(DE-2719)2810403 |
| 913 | 1 | _ | |a DE-HGF |b Forschungsbereich Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-345 |2 G:(DE-HGF)POF3-300 |v Population Studies and Genetics |x 0 |
| 914 | 1 | _ | |y 2014 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b HUM BRAIN MAPP : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-2719)1012001 |k AG Breteler 1 |l Population Health Sciences |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1012001 |
| 980 | _ | _ | |a UNRESTRICTED |
| 999 | C | 5 | |a 10.3816/CBC.2008.n.007 |9 -- missing cx lookup -- |2 Crossref |o 10.3816/CBC.2008.n.007 |
| 999 | C | 5 | |y 1995 |2 Crossref |o Brown 1995 |
| 999 | C | 5 | |y 1998 |2 Crossref |o Brown 1998 |
| 999 | C | 5 | |y 2011 |2 Crossref |o Centers for Disease C, Prevention 2011 |
| 999 | C | 5 | |a 10.3346/jkms.2001.16.3.328 |9 -- missing cx lookup -- |2 Crossref |o 10.3346/jkms.2001.16.3.328 |
| 999 | C | 5 | |a 10.1097/PPO.0b013e31818d8769 |9 -- missing cx lookup -- |2 Crossref |o 10.1097/PPO.0b013e31818d8769 |
| 999 | C | 5 | |a 10.1161/CIRCULATIONAHA.107.699579 |9 -- missing cx lookup -- |2 Crossref |o 10.1161/CIRCULATIONAHA.107.699579 |
| 999 | C | 5 | |2 Crossref |o Ruiter |
| 999 | C | 5 | |a 10.1016/j.neuroimage.2010.08.058 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.neuroimage.2010.08.058 |
| 999 | C | 5 | |y 2011a |2 Crossref |o Deprez 2011a |
| 999 | C | 5 | |a 10.1002/hbm.21033 |9 -- missing cx lookup -- |2 Crossref |o 10.1002/hbm.21033 |
| 999 | C | 5 | |a 10.2217/pgs.10.197 |9 -- missing cx lookup -- |2 Crossref |o 10.2217/pgs.10.197 |
| 999 | C | 5 | |a 10.1097/00005072-198901000-00004 |9 -- missing cx lookup -- |2 Crossref |o 10.1097/00005072-198901000-00004 |
| 999 | C | 5 | |y 2012 |2 Crossref |t Studies of the Biology and Protection of Adverse Neurological Effects of Systemic Chemotherapy Treatment in Animal Models |o Han Studies of the Biology and Protection of Adverse Neurological Effects of Systemic Chemotherapy Treatment in Animal Models 2012 |
| 999 | C | 5 | |a 10.1186/jbiol69 |9 -- missing cx lookup -- |2 Crossref |o 10.1186/jbiol69 |
| 999 | C | 5 | |a 10.1007/s10654-009-9386-z |9 -- missing cx lookup -- |2 Crossref |o 10.1007/s10654-009-9386-z |
| 999 | C | 5 | |a 10.1200/JCO.2006.06.5516 |9 -- missing cx lookup -- |2 Crossref |o 10.1200/JCO.2006.06.5516 |
| 999 | C | 5 | |a 10.1007/s10654-011-9624-z |9 -- missing cx lookup -- |2 Crossref |o 10.1007/s10654-011-9624-z |
| 999 | C | 5 | |a 10.1016/j.neurobiolaging.2008.04.008 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.neurobiolaging.2008.04.008 |
| 999 | C | 5 | |a 10.1002/cncr.22368 |9 -- missing cx lookup -- |2 Crossref |o 10.1002/cncr.22368 |
| 999 | C | 5 | |a 10.1016/S1361-8415(01)00036-6 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/S1361-8415(01)00036-6 |
| 999 | C | 5 | |a 10.1212/WNL.0b013e31822313dc |9 -- missing cx lookup -- |2 Crossref |o 10.1212/WNL.0b013e31822313dc |
| 999 | C | 5 | |a 10.1109/TMI.2009.2035616 |9 -- missing cx lookup -- |2 Crossref |o 10.1109/TMI.2009.2035616 |
| 999 | C | 5 | |a 10.1200/JCO.2011.37.0189 |9 -- missing cx lookup -- |2 Crossref |o 10.1200/JCO.2011.37.0189 |
| 999 | C | 5 | |a 10.1007/s10549-011-1888-1 |9 -- missing cx lookup -- |2 Crossref |o 10.1007/s10549-011-1888-1 |
| 999 | C | 5 | |y 2009 |2 Crossref |t ExploreDTI: A graphical toolbox for processing, analyzing, and visualizing diffusion MR data |o Leemans ExploreDTI: A graphical toolbox for processing, analyzing, and visualizing diffusion MR data 2009 |
| 999 | C | 5 | |a 10.1002/mrm.21890 |9 -- missing cx lookup -- |2 Crossref |o 10.1002/mrm.21890 |
| 999 | C | 5 | |a 10.1007/s10549-010-1088-4 |9 -- missing cx lookup -- |2 Crossref |o 10.1007/s10549-010-1088-4 |
| 999 | C | 5 | |a 10.1016/j.neuron.2006.08.012 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.neuron.2006.08.012 |
| 999 | C | 5 | |a 10.1200/JCO.2006.09.9861 |9 -- missing cx lookup -- |2 Crossref |o 10.1200/JCO.2006.09.9861 |
| 999 | C | 5 | |a 10.1016/S1474-4422(07)70326-5 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/S1474-4422(07)70326-5 |
| 999 | C | 5 | |a 10.1002/hbm.1058 |9 -- missing cx lookup -- |2 Crossref |o 10.1002/hbm.1058 |
| 999 | C | 5 | |a 10.1177/014662167700100306 |9 -- missing cx lookup -- |2 Crossref |o 10.1177/014662167700100306 |
| 999 | C | 5 | |a 10.1016/j.neuroimage.2011.07.033 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.neuroimage.2011.07.033 |
| 999 | C | 5 | |a 10.1002/ijc.22160 |9 -- missing cx lookup -- |2 Crossref |o 10.1002/ijc.22160 |
| 999 | C | 5 | |a 10.1016/j.neubiorev.2010.09.006 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.neubiorev.2010.09.006 |
| 999 | C | 5 | |a 10.1016/j.bbr.2009.02.025 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.bbr.2009.02.025 |
| 999 | C | 5 | |a 10.1016/j.neuroimage.2006.02.024 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.neuroimage.2006.02.024 |
| 999 | C | 5 | |a 10.1016/j.neuroimage.2004.07.051 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.neuroimage.2004.07.051 |
| 999 | C | 5 | |a 10.1016/j.neuroimage.2008.03.061 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.neuroimage.2008.03.061 |
| 999 | C | 5 | |a 10.1006/nimg.2002.1267 |9 -- missing cx lookup -- |2 Crossref |o 10.1006/nimg.2002.1267 |
| 999 | C | 5 | |a 10.1016/j.neuroimage.2005.01.028 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.neuroimage.2005.01.028 |
| 999 | C | 5 | |a 10.1093/jnci/90.3.210 |9 -- missing cx lookup -- |2 Crossref |o 10.1093/jnci/90.3.210 |
| 999 | C | 5 | |a 10.1001/archgenpsychiatry.2009.5 |9 -- missing cx lookup -- |2 Crossref |o 10.1001/archgenpsychiatry.2009.5 |
| 999 | C | 5 | |a 10.1016/j.neuroimage.2007.05.018 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.neuroimage.2007.05.018 |
| 999 | C | 5 | |a 10.1016/S1470-2045(10)70294-1 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/S1470-2045(10)70294-1 |
| 999 | C | 5 | |a 10.1002/mrm.21965 |9 -- missing cx lookup -- |2 Crossref |o 10.1002/mrm.21965 |
| 999 | C | 5 | |a 10.1176/jnp.2010.22.1.48 |9 -- missing cx lookup -- |2 Crossref |o 10.1176/jnp.2010.22.1.48 |
| 999 | C | 5 | |a 10.1016/j.neuroimage.2010.11.016 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.neuroimage.2010.11.016 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|